Bupropion for the Treatment of Fatigue Associated With Multiple Sclerosis

Duffy, James D.; Campbell, John

doi:10.1016/s0033-3182(94)71797-7

Cited by 10 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estimates of the prevalence of major depressive disorder range from 5% to almost 50%, depending on the diagnostic methods used [1]. Bupropion (Wellbutrin-SR ® ; GlaxoSmithKline, Philadelphia) is an atypical antidepressant, unrelated to tricyclic antidepressants or selective serotonin reuptake inhibitors, that has been used to treat chronic fatigue syndrome and fatigue associated with multiple sclerosis [62][63][64]. We identified two studies (6% of total) of bupropion sustained-release (SR) in the treatment of CRF [42,43].…”

Section: Antidepressantsmentioning

confidence: 99%

Pharmacologic Treatment of Cancer-Related Fatigue

et al. 2007

View full text Add to dashboard Cite

Fatigue is the most commonly reported symptom in patients with cancer, with a prevalence of over 60% reported in the majority of studies. This paper systematically reviews pharmacologic agents in the treatment of cancer-related fatigue (CRF). We conducted a literature review of clinical trials that assessed pharmacologic agents for the treatment of CRF. These agents include hematopoietics (for anemia), corticosteroids, and psychostimulants. Other therapeutic agents that are less well studied for CRF but are currently the focus of clinical trials include l-carnitine, modafinil, bupropion, and selective serotonin reuptake inhibitors such as paroxetine. The Oncologist 2007;12(suppl 1):43-51

show abstract

Section: Antidepressantsmentioning

confidence: 99%

Pharmacologic Treatment of Cancer-Related Fatigue

et al. 2007

View full text Add to dashboard Cite

show abstract

“…9,10 Bupropion was subsequently increased to 150 mg twice daily 1 month later. Three days after this dose augmentation, he developed visual hallucinations.…”

Section: Case Reportmentioning

confidence: 99%

“…9 For instance, NAC is a precursor of glutathione, a main antioxidant of the brain. 9 Several other actions of NAC may be relevant to its possible antidepressant activity: (1) its anti-inflammatory effects; (2) the indirect decrement of synaptic release of glutamate, and (3) the facilitation of striatal dopamine release. 9 N-acetylcysteine has antidepressant properties in the rat bulbectomy model of depression.…”

Section: N-acetylcysteine Augmentation To Tranylcypromine In Treatmenmentioning

confidence: 99%

Bupropion-Related Visual Hallucinations in a Veteran With Posttraumatic Stress Disorder and Multiple Sclerosis

Kojima

Tamai

Karino

et al. 2013

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

“…Fatigue in multiple sclerosis has been described as "a feeling of physical tiredness and lack of energy distinct from sadness or weakness" [154]. Basal ganglia mechanisms have been implicated in multiple sclerosis-related fatigue [155], and drugs that act on DA such as pemoline and buproprion have been used to treat this symptom [153,156]. Furthermore, HIV patients can also show apathy, and a recent morphometric study demonstrated that this apathy in HIV patients is accompanied by reductions in nucleus accumbens volume [157].…”

Section: Clinical Significancementioning

confidence: 99%

Role of dopamine–adenosine interactions in the brain circuitry regulating effort-related decision making: insights into pathological aspects of motivation

Salamone

Correa²,

Farrar³

et al. 2010

Future Neurol.

View full text Add to dashboard Cite

Review Dopaminergic involvement in activational aspects of motivationSimilar to other psychological constructs such as emotion and cognition, motivation is not a simple or unitary phenomenon. Motivation is a complex and multifacted process that includes many diverse components. Some aspects of motivation are related to sensations of internal and external stimuli, while other aspects of motivation are related to motor function [1]. Motivated behavior takes place in phases that represent different degrees of physical or psychological distance from the primary motivational stimulus (i.e., appetitive vs consummatory; instrumental vs consummatory; see [2][3][4]). Moreover, motivation theory and research has emphasized for several years that there are 'directional' and 'activational' aspects of motivation [5][6][7]. Directional aspects refer to the observation that the behavior of animals is directed towards or away from particular motivational stimuli. In addition, it is evident that motivated behavior can be characterized by persistence, vigor and high levels of work output; these activational aspects of motivated behavior are highly adaptive because they enable organisms to overcome challenges or work-related response costs that separate them from significant stimuli such as food [4,[8][9][10][11][12][13]. While foraging in the wild, animals can invest considerable time and can cover large areas of space in order to gain access to food or other primary motivational stimuli. Laboratory experiments have shown that animals can climb barriers, run in mazes or press levers on schedules with high input ratio requirements, in order to gain access to motivational stimuli such as food. Under some conditions the presentation of motivational stimuli can generate heightened, even excessive, levels of motor activity. In humans, impairments in behavioral activation can manifest themselves as energy-related symptoms such as psychomotor slowing, anergia and fatigue, which are features of depression, and can also be observed in other psychiatric or n eurological disorders [11].In addition to studying these behavioral processes involved in activational aspects of motivation, neuroscientists have also focused upon the brain mechanisms that are potentially involved. Several brain areas have been investigated, but one of the neural systems most closely associated with behavioral activation is the dopamine (DA) innervation of the nucleus accumbens [8][9][10][11]14,15]. Although the mesolimbic DA system has consistently been linked to aspects of drug reinforcement, and is often referred to as some type of 'pleasure' or 'reward' center, recent Brain dopamine, particularly in the nucleus accumbens, has been implicated in activational aspects of motivation and effort-related processes. Accumbens dopamine depletions reduce the tendency of rats to work for food, and alter effort-related decision making, but leave aspects of food motivation such as appetite intact. Recent evidence indicates that the purine neuromodulator adenosine, largely thr...

show abstract

Bupropion for the Treatment of Fatigue Associated With Multiple Sclerosis

Cited by 10 publications

References 3 publications

Pharmacologic Treatment of Cancer-Related Fatigue

Pharmacologic Treatment of Cancer-Related Fatigue

Bupropion-Related Visual Hallucinations in a Veteran With Posttraumatic Stress Disorder and Multiple Sclerosis

Role of dopamine–adenosine interactions in the brain circuitry regulating effort-related decision making: insights into pathological aspects of motivation

Contact Info

Product

Resources

About